Intellia Therapeutics(NTLA.US)和再生元(REGN.US)联合宣布CRISPR首个临床试验结果公布

$Aridis制药(ARDS)$
Licensed the CRISPR gene editing technology from the Broad Institute of MIT and Harvard. CRISPR is a component of the ʎPEXTM mAb discovery and production platform technology.
Entered into a ʎPEX out-licensing and product discovery agreement with Kermode Biotechnologies, Inc. on vaccines and mAbs for zoonotic viruses, which are animal viruses that have the ability to infect humans and potentially lead to a viral pandemic.

期待超级战士的诞生，超级血清投入到军事上，oh yeah

史诗级变革

保持关注